Literature DB >> 27852702

Gas6/AXL Signaling Regulates Self-Renewal of Chronic Myelogenous Leukemia Stem Cells by Stabilizing β-Catenin.

Yanli Jin1, Danian Nie2, Juan Li3, Xin Du4, Yuhong Lu5, Yangqiu Li5, Chang Liu1, Jingfeng Zhou1, Jingxuan Pan6,7.   

Abstract

Purpose: Quiescent leukemia stem cells (LSC) are important resources of resistance and relapse in chronic myelogenous leukemia (CML). Thus, strategies eradicating CML LSCs are required for cure. In this study, we discovered that AXL tyrosine kinase was selectively overexpressed in primary CML CD34+ cells. However, the role of AXL and its ligand Gas6 secreted by stromal cells in the regulation of self-renewal capacity of LSCs has not been well investigated.Experimental Design: The function of CML CD34+ cells was evaluated by flow cytometer, CFC/replating, long-term culture-initiating cells (LTC-IC), CML mouse model driven by human BCR-ABL gene and NOD-scid-IL2Rg-/- (NSI) mice.
Results: AXL was selectively overexpressed in primary CML CD34+ cells. AXL knockdown reduced the survival and self-renewal capacity of human CML CD34+ cells. Pharmacologic inhibition of AXL reduced the survival and self-renewal capacity of human CML LSCs in vitro and in long-term grafts in NSI mice. Human CML CD34+ cells conscripted bone marrow-derived stromal cells (BMDSC) and primary mesenchymal stem cells (MSC) to secrete Gas6 to form a paracrine loop that promoted self-renewal of LSCs. Suppression of AXL by shRNA and inhibitor prolonged survival of CML mice and reduced the growth of LSCs in mice. Gas6/AXL ligation stabilizes β-catenin in an AKT-dependent fashion in human CML CD34+ cells.Conclusions: Our findings improve the understanding of LSC regulation and validate Gas6/AXL as a pair of therapeutic targets to eliminate CML LSCs. Clin Cancer Res; 23(11); 2842-55. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27852702     DOI: 10.1158/1078-0432.CCR-16-1298

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  21 in total

Review 1.  Parallels between hematopoietic stem cell and prostate cancer disseminated tumor cell regulation.

Authors:  Frank C Cackowski; Russell S Taichman
Journal:  Bone       Date:  2018-02-26       Impact factor: 4.398

Review 2.  Regulation of Malignant Myeloid Leukemia by Mesenchymal Stem Cells.

Authors:  Zhenya Tan; Chen Kan; Mandy Wong; Minqiong Sun; Yakun Liu; Fan Yang; Siying Wang; Hong Zheng
Journal:  Front Cell Dev Biol       Date:  2022-06-08

3.  Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant.

Authors:  Bei Jin; Chengyan Wang; Yingying Shen; Jingxuan Pan
Journal:  Cell Death Dis       Date:  2018-01-22       Impact factor: 8.469

4.  The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal melanoma in vitro and in vivo.

Authors:  Jingfeng Zhou; Bei Jin; Yanli Jin; Yizhi Liu; Jingxuan Pan
Journal:  Theranostics       Date:  2017-04-03       Impact factor: 11.556

Review 5.  Cancer Metastases to Bone: Concepts, Mechanisms, and Interactions with Bone Osteoblasts.

Authors:  Alison B Shupp; Alexus D Kolb; Dimpi Mukhopadhyay; Karen M Bussard
Journal:  Cancers (Basel)       Date:  2018-06-04       Impact factor: 6.639

6.  ssExpression level of GAS6-mRNA influences the prognosis of acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation.

Authors:  Xinrui Yang; Jinlong Shi; Xinpei Zhang; Gaoqi Zhang; Jilei Zhang; Siyuan Yang; Jing Wang; Xiaoyan Ke; Lin Fu
Journal:  Biosci Rep       Date:  2019-05-21       Impact factor: 3.840

7.  AXL Inhibition in Macrophages Stimulates Host-versus-Leukemia Immunity and Eradicates Naïve and Treatment-Resistant Leukemia.

Authors:  Irene Tirado-Gonzalez; Arnaud Descot; Devona Soetopo; Aleksandra Nevmerzhitskaya; Alexander Schäffer; Ivan-Maximilano Kur; Ewelina Czlonka; Carolin Wachtel; Ioanna Tsoukala; Luise Müller; Anna-Lena Schäfer; Maresa Weitmann; Petra Dinse; Emily Alberto; Michèle C Buck; Jonathan Jm Landry; Bianka Baying; Julia Slotta-Huspenina; Jenny Roesler; Patrick N Harter; Anne-Sophie Kubasch; Jörn Meinel; Eiman Elwakeel; Elisabeth Strack; Christine Tran Quang; Omar Abdel-Wahab; Marc Schmitz; Andreas Weigert; Tobias Schmid; Uwe Platzbecker; Vladimir Benes; Jacques Ghysdael; Halvard Bonig; Katharina S Götze; Carla V Rothlin; Sourav Ghosh; Hind Medyouf
Journal:  Cancer Discov       Date:  2021-06-08       Impact factor: 39.397

8.  Targeting protein lysine methyltransferase G9A impairs self-renewal of chronic myelogenous leukemia stem cells via upregulation of SOX6.

Authors:  Min Zhou; Xiuli Zhang; Chang Liu; Danian Nie; Shuyi Li; Peilong Lai; Yanli Jin
Journal:  Oncogene       Date:  2021-04-30       Impact factor: 9.867

9.  AXL receptor tyrosine kinase: a possible therapeutic target in acute promyelocytic leukemia.

Authors:  Mariam Fatima; Salik Javed Kakar; Fazal Adnan; Khalid Khan; Afsar Ali Mian; Dilawar Khan
Journal:  BMC Cancer       Date:  2021-06-17       Impact factor: 4.430

10.  Transcriptional upregulation of c-MYC by AXL confers epirubicin resistance in esophageal adenocarcinoma.

Authors:  Jun Hong; Selma Maacha; Abbes Belkhiri
Journal:  Mol Oncol       Date:  2018-11-05       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.